Table 16.
Change in serum high-density lipoprotein cholesterol in individual studies
| Study |
Serum high-density lipoprotein cholesterol (mg/dL) |
P value | P value between groups | ||
| Group | Baseline | Study completion | |||
| Kuchay et al[11] | Empagliflozin | 42.0 (12.0) | 45.0 (12.0) | 0.087 | 0.752 |
| Control | 45.0 (15.0) | 47.0 (12.0) | 0.097 | ||
| Ito et al[12] | Ipragliflozin | 48.9 (9.3) | 54.7 (10.4) | < 0.05 | 0.82 |
| Pioglitazone | 47.4 (11.6) | 52.7 (13.5) | < 0.05 | ||
| Eriksson et al[14] | Placebo | 51.4 (14.9) | -0.4 (5.0)1 | - | - |
| Omega-3 CA | 49.9 (14.1) | +0.4 (3.2)1 | - | Non-significant2 | |
| Dapagliflozin | 49.9 (9.5) | +0.4 (4.8)1 | - | Non-significant2 | |
| O + D | 51.4 (10.2) | +1.6 (5.0)1 | - | Non-significant2 | |
| Ohki et al[15] | Ipragliflozin | 42.0 (40.0-50.0) | 44.0 (42.0-59.0) | 0.01 | - |
| Seko et al[16] | SGLT-2 inhibitor | 53.9 (2.5) | 55.4 (2.6) | 0.043 | - |
| Sitagliptin | 54.8 (3.3) | 55.6 (2.3) | 0.531 | ||
| Sumida et al[18] | Luseogliflozin | 55.6 (11.7) | 57.5 (13.4) | 0.062 | - |
1
Change from baseline.
2
Compared to placebo.
CA: Carboxylic acid; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.